Financial & competing interests disclosures:
P Chilton has no personal conflict of interest, however, she is listed as Key Personnel on two NIH subcontracts through GSK/Corixa, one to develop MPL mimetics as vaccine adjuvants; the principal investigator is David Johnson. The other focuses on synthetic TLR7/8 agonists; the principal investigator is Jay Evans. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.